Sequoia Financial Advisors LLC Has $4.35 Million Stock Holdings in Stryker Co. (NYSE:SYK)

Sequoia Financial Advisors LLC lifted its stake in shares of Stryker Co. (NYSE:SYK - Free Report) by 7.5% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 12,074 shares of the medical technology company's stock after purchasing an additional 838 shares during the quarter. Sequoia Financial Advisors LLC's holdings in Stryker were worth $4,347,000 as of its most recent SEC filing.

Several other large investors also recently modified their holdings of the stock. J. W. Coons Advisors LLC grew its holdings in shares of Stryker by 0.7% during the 4th quarter. J. W. Coons Advisors LLC now owns 3,653 shares of the medical technology company's stock worth $1,315,000 after purchasing an additional 26 shares in the last quarter. Opal Wealth Advisors LLC grew its holdings in shares of Stryker by 1.6% during the 4th quarter. Opal Wealth Advisors LLC now owns 1,816 shares of the medical technology company's stock worth $654,000 after purchasing an additional 28 shares in the last quarter. Lindbrook Capital LLC lifted its position in shares of Stryker by 2.0% during the 4th quarter. Lindbrook Capital LLC now owns 1,407 shares of the medical technology company's stock worth $507,000 after buying an additional 28 shares during the last quarter. Alhambra Investment Management LLC lifted its position in shares of Stryker by 1.5% during the 4th quarter. Alhambra Investment Management LLC now owns 1,997 shares of the medical technology company's stock worth $719,000 after buying an additional 29 shares during the last quarter. Finally, JFS Wealth Advisors LLC lifted its position in shares of Stryker by 4.4% during the 4th quarter. JFS Wealth Advisors LLC now owns 687 shares of the medical technology company's stock worth $247,000 after buying an additional 29 shares during the last quarter. 77.09% of the stock is owned by institutional investors and hedge funds.

Stryker Trading Down 0.0 %

NYSE SYK opened at $363.79 on Friday. The business has a 50 day simple moving average of $382.87 and a 200 day simple moving average of $373.26. Stryker Co. has a one year low of $314.93 and a one year high of $406.19. The stock has a market capitalization of $138.81 billion, a P/E ratio of 46.88, a P/E/G ratio of 2.93 and a beta of 0.95. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.95 and a quick ratio of 1.32.

Remove Ads

Stryker (NYSE:SYK - Get Free Report) last released its earnings results on Tuesday, January 28th. The medical technology company reported $4.01 EPS for the quarter, topping the consensus estimate of $3.87 by $0.14. Stryker had a return on equity of 23.58% and a net margin of 13.25%. During the same quarter in the previous year, the company earned $3.46 earnings per share. Research analysts expect that Stryker Co. will post 13.47 earnings per share for the current year.

Stryker Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st will be paid a $0.84 dividend. The ex-dividend date is Monday, March 31st. This represents a $3.36 dividend on an annualized basis and a yield of 0.92%. Stryker's dividend payout ratio (DPR) is presently 43.30%.

Insider Buying and Selling at Stryker

In other Stryker news, Director Allan C. Golston sold 2,458 shares of the firm's stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $383.07, for a total value of $941,586.06. Following the completion of the sale, the director now owns 14,895 shares of the company's stock, valued at approximately $5,705,827.65. This trade represents a 14.16 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Ronda E. Stryker sold 201,392 shares of the firm's stock in a transaction that occurred on Friday, January 31st. The shares were sold at an average price of $392.24, for a total value of $78,993,998.08. Following the completion of the sale, the director now directly owns 3,642,075 shares of the company's stock, valued at $1,428,567,498. This trade represents a 5.24 % decrease in their position. The disclosure for this sale can be found here. Insiders own 5.90% of the company's stock.

Analyst Ratings Changes

Several analysts recently weighed in on the company. StockNews.com downgraded Stryker from a "buy" rating to a "hold" rating in a research report on Thursday, March 6th. Barclays upped their price objective on Stryker from $418.00 to $443.00 and gave the stock an "overweight" rating in a research report on Monday, February 10th. Canaccord Genuity Group upped their price objective on Stryker from $420.00 to $435.00 and gave the stock a "buy" rating in a research report on Wednesday, January 29th. Stifel Nicolaus upped their price objective on Stryker from $400.00 to $440.00 and gave the stock a "buy" rating in a research report on Wednesday, January 29th. Finally, Royal Bank of Canada increased their target price on Stryker from $425.00 to $435.00 and gave the company an "outperform" rating in a research report on Wednesday, January 29th. Five equities research analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company's stock. According to MarketBeat.com, Stryker has an average rating of "Moderate Buy" and an average price target of $421.90.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.